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D iabetes mellitus is a lifelong metabolic disorder characterised by a chronically elevated reduced [AQ1 isn’t it a lack of insulin secretion?] blood insulin secretion, [impaired] insulin action or both (Kumar et al, 2003 [AQ2 v old ref please 
update]). The prevalence of this condition is escalating at an 
unprecedented rate across the world without sign of abatement. 
In the UK, for example, an estimated 3.7 million people are 
living with a diagnosis of diabetes, an increase of 100 000 since 
2017 (Diabetes UK, 2017 [AQ3 should this be 2018, as I don’t 
think they get the figures that quickly!]). The global picture 
is equally worrying, with 425 million currently estimated to 
have diabetes, with the figure expected to peak at 629 million 
in 2045. If longevity is taken into account, the figure could 
reach 693 million (International Diabetes Federation, 2017). 
In an attempt to halt the problem, health professionals must 
be given effective training on diabetes prevention and care, in 
order to reduce the devastating human, social and economic 
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ABSTRACT
New ways of measuring blood glucose bring hope of easing the burden of 
diabetes management for patients living with the conditions. The smart tattoo 
is an innovation that represents a nascent nanotechnology, which is designed 
to be implanted within the skin to provide continuous and reliable glucose 
detection for individuals diagnosed with diabetes mellitus. The potential 
benefits of the smart tatto are compelling not only due to the potential of these 
nanodevices to prevent diabetic complications and decrease the related social 
costs, but also due to ease of use and relative user comfort. However, despite 
the advantages of the smart tattoo, it is important that health professionals, in 
embracing nanotechnology, understand the ethical implications of using these 
innovative devices.
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impact of the condition (Meetoo, 2013).
Diabetes management
People with diabetes constantly walk a tightrope between 
strict glycaemic control to delay and/or slow the progression 
of micro- and macrovascular complications. One of the core 
components of self-care management therefore requires people 
with type 1 diabetes mellitus (T1DM) and those with type 2 
diabetes mellitus (T2DM) treated with insulin to assess glycaemic 
variability by self-monitoring blood glucose (SMBG) levels 
(Holt, 2014; Eborall et al, 2015; National Institute for Health 
and Care Excellence (NICE), 2015). Evidence from several 
longitudinal landmark studies have conclusively demonstrated 
that improved glycaemic control reduces the risk of diabetes-
related complications in T1DM (Nathan et al, 1993) and T2DM 
(UK Prospective Diabetes Trial, 1998; Gerstein et al, 2008; 
Simon et al, 2008; Holman et al, 2008) and the Kumamoto 
study (Ohkubo et al, 1995 [AQ5 are there no recent studies?]).
To prevent vascular events, contemporary diabetes 
management places heavy emphasis on individuals to manage 
their condition by undertaking a number of behavioural 
activities, such as healthy eating, taking medication, healthy 
coping, physical exercise, problem solving, blood pressure and 
blood glucose monitoring (Meetoo, 2013). These diabetes self-
care behaviours are frequently contingent with the results of 
SMBG (Tomsky et al, 2008), which is undertaken through a 
variety of means, dependent on parameters that are individual 
to each person with diabetes (Poolsup et al, 2009). Unlike 
HbA1c, which reflects blood glucose levels over the preceding 
three months, SMBG provides immediate information on a 
person’s glycaemic level, thereby acting as an important guide 
for adjusting all factors that affect glycaemic control on a more 
timely basis (Barnett et al, 2008). 
Blood glucose monitoring 
Currently, people with T1DM and those managed with 
sulphonylureas measure their blood glucose by intermittent 
finger-prick capillary blood sampling. The blood is then placed 
on a sensor test strip that is read by a handheld electronic 
reader that uses screen-printed electrodes to measure blood 
glucose concentration (Wang, 2008). This provides rapid and 
accurate measurements of blood glucose without the need for 
laboratory analysis. 
However, there are limitations. For example, other than being 
painful, uncomfortable and likely to lead to non-adherence 
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(Heinemann, 2008), this procedure cannot be performed when 
the person is asleep or at those critical times when dangerous 
fluctuations in blood glucose concentrations between tests are 
missed [AQ6 meaning? Please rewrite for clarity] (Burge et 
al, 2008; Pickup et al, 2008). However, while a standard blood 
glucose monitor for SMBG provides discrete and highly accurate 
BG levels, these readings do not predict future blood glucose 
levels. The taking and testing of finger-prick blood samples is 
arguably just one unwelcome consequence of having diabetes. 
This approach currently represents the only practical way for 
most patients to manage their glucose levels, but it is becoming 
more apparent that the traditional method of recording blood 
glucose levels needs to be replaced by a more sophisticated and 
pain-free technology. 
Blood glucose monitoring with nanotechnology
If the best way to monitor the outcome of an important 
matter would be through the use of a continuously running 
security camera rather than with an intermittently functioning 
high-quality reflex camera, then it would be logical to suggest 
that the best way to monitor changes in glycaemia would be 
via a continuous glucose monitor rather than one yielding 
intermittent blood glucose results (Figure 1). The development 
of a completely reliable and accurate technology for a minimally 
or non-invasive and continuous glucose sensing is therefore 
considered a would-be ‘holy grail’ of diabetes care (Clarke et 
al, 2009; Hughes, 2009). 
Over the decades, a single, convenient way of enabling people 
with diabetes to monitor their blood glucose levels has eluded 
medical science. Recently, however, one promising technology, 
known as nanotechnology, has brought the prospect within 
easy reach by enabling the implantation of glucose biosensors, 
known as ‘smart tattoos’ in subcutaneous tissue (Brown et al, 
2006; Stein et al, 2007 [AQ7 old refs, please update]). Realisation 
of such a monitor would, according to Klonoff (2007) [AQ8 
old ref, please update], serve such purposes as: 
 ■ Detecting and predicting hypoglycaemia and hyperglycaemia 
in real time
 ■ Assessing mean glycaemia
 ■ Determining the amount of glycaemic variability.
Overview of nanotechnology
It is beyond the scope of this article to present a detailed 
explanation of nanotechnology, but to put it briefly it is the 
‘science of the small’ (Marchant, 2009). It has been hailed as the 
‘next industrial revolution’ and promises to have a substantial 
impact on many areas of our lives (National Technology 
Initiative, 2000; Maynard, 2006 [AQ9 old refs, please update]). 
The prefix ‘nano’, which originates from the Greek word nanos, 
means ‘dwarf ’, represents 1 billionth of a meter (1 nm=10-9), a 
dimension that is invisible to the naked eye. To gain a sense of 
scale, the diameter of the double-helix DNA molecule is 2 nm, 
that of a human hair about 100 000 nm, while a red blood cell 
is 7000 nm across. Atoms are smaller than 1 nm whereas the 
size of molecules, including some proteins, ranges between 
1 nm and larger [AQ10 how large? this can’t be called a range] 
(Whitesides, 2003) [AQ11 v old refs, please update]. 
At this dimension, known as nanoscale, structures and 
devices often have fundamentally altered properties, including 
metabolite sensing, controlled porosity, biocompatibility and 
the ability to target tissues and molecules in the body. 
When this science is applied specifically to the problems of 
medicine, it is referred to as ‘nanomedicine’ (Freitas, 2005 [AQ12 
v old refs, please update]). The human body has configured 
many of its biocomponents as nanostructures, including 
proteins, mitochondria, ion channels, membranes, secretory 
granules and lysosomes. This has enabled the manufacture of 
new nanomaterials and structures with application in medicine, 
ranging from nanoparticles, capsules, films and tubes to complex 
molecules such as fullerenes (Kroto, 1985). The appeal of 
nanomedicine therefore stems from the fact that nanoparticles 
can act as carriers to deliver drugs to targeted cells and tissue 
sites, including the blood-brain barrier, which are currently not 
entirely possible [AQ13 It’s either possible or not, pls clarify] 
(Oberdörster et al, 2004 [AQ14 v old ref, please update/delete]; 
Juliano, 2012). 
The smart tattoo
A simple and convenient way of enabling people with diabetes 
to monitor their own blood sugar levels has eluded medical 
science. In recent years, however, continuous glucose monitoring 
has been available for selected patients via needle-type sensors 
inserted under the skin. To date, these devices have yet to 
achieve optimal accuracy and reliability, or widespread use. 
So the potential benefits of a radical new technique that not 
Figure 1. (a) Conventional intermittent glucose monitoring with an enzyme 
electrode strip (b) Continuous glucose monitoring with smart tattoos (Heo and 
Takeuchi, 2013)
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only eliminates the need for blood samples, but also delivers 
continuous information are highly desirable. To this end, 
advances in nanometrology (measurement at nanoscale) are 
bringing this prospect within reach with the development of 
smart tattoos, also known as nano tattoos (Stein et al, 2007 
[AQ15 old ref, please update]).
The smart tattoo represents a nascent technology designed 
to be implanted within the skin to provide continuous, reliable 
glucose detection predominantly for people with T1DM. Its 
potential benefits are compelling, not only for its ability to 
prevent diabetes-related complications and reduce related social 
costs, but also for its ease of use and relative patient comfort. 
The smart tattoo consists of an intradermally embedded array 
of biosensors that are exposed to interstitial fluid, enabling 
the measurement of local changes in glucose, which correlate 
with blood glucose levels (Caplin et al, 2003 [AQ16 v old 
ref, please update]). The implant emits visible colour changes 
corresponding to the glucose levels in the bloodstream, which 
in turn can be interrogated non-invasively through the skin 
using a simple optical device (Figure 2) (Long et al, 2008). 
For example, the smart tattoo is designed to alert the person 
when their blood glucose level is high, and insulin is required. 
The nanomaterials and nanosensors that are part of the smart 
tattoo have therefore significant advantages because of their 
small size. They have a high surface area to volume ratio, as well 
as enhanced optical properties that allow for the improvement 
of the accuracy and size of the sensors for treatment of diabetes 
[AQ17 meaning? please rewrite] (Cash and Clark, 2010).
Advantages of smart tattoo
It may in theory be accepted that just taking one or two blood 
glucose readings from finger-prick capillaries is sufficient when 
addressing SMBG. However, evidence has demonstrated how 
readings are missed when blood glucose is not monitored 
continuously (Burge et al, 2008; Pickup et al, 2008). This can lead 
to undesired diabetes consequences, specifically hypoglycaemia 
(Cash and Clark, 2010). On the other hand, continuous readings 
empower the individual to successfully prevent and/or manage 
adverse diabetes events. This can also prove to be advantageous 
by enabling the individual to have a better understanding of 
their blood glucose levels at any given point. 
The other potential benefits of a smart tattoo are compelling 
not only for its ability to prevent diabetes-related complications 
and decrease related social costs, but also for its ease of use 
and relative comfort. However, unlike regular tattoos, smart 
tattoos would be only temporary and would be replaced weekly 
or monthly to account for sensor migration and the loss of 
signal owing to degradation. This method would eliminate 
or reduce the need for patients to take blood samples, while 
allowing data to be collected continuously. It also minimises the 
chances for infection at the implantation site and avoids other 
complications of implanted devices, such as capsule formation 
and the accompanying decreases in glucose transport (Mou 
et al, 2010). 
Arguably, the smart tattoo will make obsolete the current 
glucose measuring standard of the finger prick, a method 
widely considered suboptimal in diagnostic efficiency and 
patient comfort. In the long term, the smart tattoo also has 
the potential to decrease associated economic costs.
Disadvantages of the smart tattoo
It is envisaged that the production and application of smart 
tattoos could prove costly. For this technology to be worthwhile, 
in this regard a number of factors need be addressed. For 
example, it is imperative that this technology is tested in realistic, 
clinical samples even for proof-of-concept design (Cash and 
Clark, 2010). Second, the cost of smart tattoos needs to be 
justified by comparing them with other commercially available 
nanosensors. Finally, to have an impact on diabetes, smart tattoos 
must demonstrate a substantial advantage over current methods 
through significant improvements in accuracy without incurring 
additional costs. 
The emerging trends in medical technology mean that the 
smart tattoo will be a welcome addition to the available range 
of blood glucose meters. The Freestyle Libre, a flash glucose 
monitoring system currently available on the NHS across the 
four UK countries after the individual has met certain criteria is 
perhaps the closest link to the smart tattoo. In the case of drivers, 
although interstitial blood glucose values are not an acceptable 
form of evidence for safe driving, this pain-free technology will 
arguably be welcomed by people whose diabetes experience 
is underpinned by blood glucose monitoring. Furthermore, 
such a meter will provide people with diabetes with a sense of 
empowerment, control and motivation in understanding and 
managing their condition (Stephens, 2014). 
Controversy and clinical benefits
The cost benefit of technologies is an important aspect of care. 
However, health professionals need to be aware that there will 
always be some variation in results among studies. This may 
range from differences in patient populations to the subtleties 
of individual studies’ experimental design and protocols, and 
variability in how the protocol was implemented. For example, 
factors such as the Hawthorne effect (which describes the 
change in behaviour when people are being observed), choice of 
endpoints and random statistical fluctuations can all contribute 
to the heterogeneity of results. 
It is noteworthy that perfect adherence to a self-care regimen 
Figure 2. Non-invasive optical instrumentation for measuring 
blood glucose
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cannot be expected. In many types of studies that involve dosage 
titration of pharmaceutical agents, one does not expect any 
differences in HbA1c. Rather, one needs to consider HbA1c 
and the risk of hypoglycaemia simultaneously (Rodbard, 2015; 
Vigersky, 2015). When evaluating a CGM [AQ18 computer 
generated model?] technology, the question should not be: 
‘Did the use of smart tattoo (or other similar technology such 
as CGM) result in a change in HbA1c?’, nor should it be: ‘Did 
the use of smart tattoo result in a favourable change in the 
risk of hypoglycaemia?’ Instead, the question posed should be: 
‘Did the introduction of the smart tattoo result in a change in 
the relationship between risk of hypoglycaemia and HbA1c 
achieved?’ (Rodbard, 2015; Vigersky, 2015).
Smart tattoos and implications for nursing
Nursing prides itself on being at the patient’s side in times of 
need, whether in hospital or in the community, and the social 
contract is based on a relationship for providing holistic care 
throughout the care continuum (Meetoo and Lappin, 2009). 
Nanotechnology, other than having the potential to redefine 
health and approaches to care delivery, promises a transition 
from treating diseases across populations to a person-centred 
approach focused on ‘personalised medicine’ (Vlasses and 
Smeltzer, 2007 [AQ19 old ref, please update]). For example, 
implants of nanotransmitters and nanosensors would allow 
individuals to access data transmitted from biochips monitoring 
such familial diseases as primary hypercholesterolaemia. This is 
particularly important in allowing affected individuals to take 
appropriate action to prevent the development of diabetes or 
diabetes-related diseases. 
In the case of people with diabetes, for example, a 
hyperglycaemic event could send a signal to the care team 
to prompt initialisation of a customised treatment plan, while 
nanoparticles could be programmed to administer insulin without 
a clinician’s direct intervention. In time, nanotechnology will 
increasingly become a diagnostic and therapeutic enabler for the 
diabetes healthcare team and other health professionals, as well 
as helping people with diabetes to take more ownership of their 
condition. The continued development of personalised medicine 
will not only need a time commitment from carers, but will also 
require a paradigm shift from consumers as patients to consumers 
as partners in the decision-making process (Ullman-Cullere et 
al, 2007 [AQ20 old ref, please update]). This kind of personalised 
medicine will mean that nurses will need to be knowledgeable 
about the potential adverse effects of nanotechnology, an area 
known as nanotoxicology. The aim of this scientific discipline 
is to determine the extent to which the toxic properties of 
nanomaterials threaten human beings (Guadagnini et al, 2015) 
and the environment (Malysheva et al, 2015). Similarly, serious 
consideration will need to be given, for example, to the prevention 
of accidental ingestion of nanomaterials during treatment delivery. 
Education 
Over-reliance on nanotechnology devices could lead health 
professionals to assume that they are receiving all the data 
when in fact this may not be the case (Lewis, 2001 [AQ21 
v old ref, please update]). Technological dependence could 
reduce interprofessional communication, while education for 
students and trained practitioners through curricular design 
will be essential to ensure that staff are knowledgeable about 
the principles underpinning the safe use of nanomaterials. 
Furthermore, a model of care that includes the provision of 
round-the-clock nanotechnology support for consumers and 
nurses will need to be devised and implemented. 
Disruptive innovations, such as nanotechnology in health, 
will inevitably transform how nursing is taught (Kelly, 2016). 
The use of nanomaterials in nursing, for example, could be 
the impetus for curricular modifications to educate students 
and practitioners about the application, control and safe uses 
of nanomedicines. The continuous emergence of technological 
innovations may well result in more empowered healthcare 
consumers at the centre of a well-informed and knowledgeable 
care team. In achieving this objective, innovative teaching 
strategies will need to be embraced by nurse educators, who 
must also be prepared for the teacher-learner relationship to 
alter in line with the changing needs of the workforce. In 
additon, the key nursing philosophies of problem-based learning, 
evidence-based practice and patient-centred care will need to 
be revisited in the context of technology if they are to remain 
at the core of education. 
Nurses will need to become even more responsible for 
engaging and driving their own learning journey in an 
heutagogical approach (Hase and Kenyon, 2001). For ongoing 
development nurse leaders and educators need to make use 
of social media platforms to facilitate discussion among their 
fellow health professionals and also improve the translation of 
evidence into practice (Moorley and Chinn, 2016). To be ready 
for this seismic shift nurse educators must therefore have an 
open-mind set to emerging methods and modalities of learning 
and cultivate a lifelong learning culture. Embracing the process 
of learning and unlearning both at organisational and individual 
level will be essential.
Ethical considerations
The implementation of nanotechnology will inevitably have 
ethical implications. Some hold the view that there will be a 
need to develop new ethical guidelines (Thompson, 2007 [AQ22 
v old ref, please update]), but others contest this (Mnyusiwalla et 
al, 2003 [AQ23 v old ref, please update]). Given the unknown 
future design of nanotechnology, Ebbesen et al (2006a; 2006b) 
[AQ24 old refs, please update] are nevertheless confident that 
the open-ended nature of Beauchamp and Childress’s (2001) 
principalist model (autonomy, beneficence, nonmaleficence 
and justice) is sufficiently sensitive to address emerging ethical 
issues in nanotechnology. 
It will be equally important for nanotechnology nurses to be 
actively involved in contributing to policy-making decisions as 
well as assisting patients in understanding and consenting to the 
use of their data, protecting privacy and ensuring that there are 
mechanisms that allow them to withdraw from participation. 
Ultimately, however, everyone is likely to require an advocate 
for the safe and ethical use of nanomaterials in such areas as 
medical care, the environment, industrial health and the fiscal 
allocation of research (Traynor, 2006 [AQ25 v old ref, please 
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update]). nanotechnology, therefore, has the potential to drive 
down the costs of care and to create healthy communities that 
need to use less, rather than more, health care.
Technological dependence could reduce interprofessional 
communications, and education for students and trained 
practitioners through curricular design will be essential 
to ensure that staff are knowledgeable about the principles 
underpinning the safe use of nanomaterials. Furthermore, a 
model of care providing round-the-clock nanotechnology 
support for consumers and nurses will need to be devised and 
implemented. The advent of nanotechnology will have new 
implications for clinicians. The concept of routine care could 
disappear in a world where everything is likely to be customised 
for individuals presenting with strange or unusual symptoms 
because the software or minute circuits of the nanomaterials 
have become infected with viruses (Meetoo and Lappin, 2009).
Conclusion
This article attempted to review smart tattoo as one of the key 
technologies most likely to be available in the near future for real 
time continuous blood glucose monitoring. Arguably, DM can 
be viewed as a condition of numbers where those affected are 
asked to monitor their blood glucose levels, insulin doses, exercise, 
calories, blood pressure and severity of symptoms on numerical 
scales. With so many numbers from so many self-care activities to 
keep track of, people with diabetes can benefit from monitoring 
devices that measure, display, transmit, store and analyse real time 
data (Kerr, 2010). Smart tattoo seems to be one such technology 
that promises to change the monitoring of blood glucose.
In today’s health care, Morrison (2000:203 [AQ26 v old ref, 
please update]) writes that ‘organ and body functions are restored 
while the whole patient is ignored. The system is failing to serve’. 
In the context of technology and to avoid Morrison’s prophetic 
statement, it is imperative that health professionals embrace 
nanotechnology which promises to revolutionise medicine in 
the 21st century by eradicating diseases and improving  the 
quality of people’s life. The smart tattoo represents a significant 
and revolutionary technological advancement in monitoring 
blood glucose and maintaining it within normal parameters to 
prevent micro- and macrovascular complications. 
Continued technological progress, as well as enabling 
health professionals to develop new and innovative approach 
to dealing with diabetes, has the potential to decrease the 
burden of diabetes management on the patients themselves. 
Furthermore, such progress will continue to improve patient 
care and its delivery and may one day lead to fully automated 
treatment systems for people with this condition. It is to be 
hoped that it is just a matter of time before the management 
of diabetes is overhauled, thus reversing the current concept of 
non-adherence as an exception rather than the norm. While 
embracing nanotechnology, it is equally important for health 
professionals not to ignore the ethical implications of the 
smart tattoo from its inception through ongoing research and 
development to implementation. BJN
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KEY POINTS
 ■ Diabetes mellitus is characterised by chronically elevated blood 
glucose levels
 ■ Maintaining blood glucose within the recommended parameters 
is important to prevent or slow the development of micro and 
macrovascular complications 
 ■ The smart tattoo is a revolutionary technological advancement designed to 
continually monitor blood glucose levels in real time
 ■ In revolutionising health care, nanomedicine will inevitably have an impact 
on nursing as a profession
 ■ Nurses need to extend their knowledge of ethics to proactively debate the 
ethical dimension of nanotechnology
CPD reflective questions [AQ32: can you add 3/4 reflective questions to 
encourage readers to reflect on their practice. Here are examples:
 ■ What can you do to enhance the safety of patients in your own clinical setting? 
 ■ Are there particular features of your clinical setting that may contribute to your patient feeling unsafe?
 ■ Considering the seven themes, which can you identify as being one on which you could further reflect and consider 
with your wider team?
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